Cancer Gene Therapy-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Cancer Gene Therapy-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Cancer Gene Therapy industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Cancer Gene Therapy 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Cancer Gene Therapy worldwide and market share by regions, with company and product introduction, position in the Cancer Gene Therapy market
Market status and development trend of Cancer Gene Therapy by types and applications
Cost and profit status of Cancer Gene Therapy, and marketing status
Market growth drivers and challenges
The report segments the global Cancer Gene Therapy market as:
Global Cancer Gene Therapy Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Cancer Gene Therapy Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Gene Induced Immunotherapy
Oncolytic Virotherapy
Gene Transfer
Global Cancer Gene Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Diagnostics Centers
Research Institutes
Global Cancer Gene Therapy Market: Manufacturers Segment Analysis (Company and Product introduction, Cancer Gene Therapy Sales Volume, Revenue, Price and Gross Margin):
Adaptimmune
GlaxoSmithKline
Bluebird bio
Merck
Celgene
Shanghai Sunway Biotech
BioCancell
Shenzhen SiBiono GeneTech
SynerGene Therapeutics
OncoGenex Pharmaceuticals
Genelux Corporation
Cell Genesys
Advantagene
GenVec
BioCancell
Celgene
Epeius Biotechnologies
Introgen Therapeutics
Ziopharm Oncology
Shenzhen SiBiono GeneTech
Altor Bioscience
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Cancer Gene Therapy-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Cancer Gene Therapy industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Cancer Gene Therapy 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Cancer Gene Therapy worldwide and market share by regions, with company and product introduction, position in the Cancer Gene Therapy market
Market status and development trend of Cancer Gene Therapy by types and applications
Cost and profit status of Cancer Gene Therapy, and marketing status
Market growth drivers and challenges
The report segments the global Cancer Gene Therapy market as:
Global Cancer Gene Therapy Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Cancer Gene Therapy Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Gene Induced Immunotherapy
Oncolytic Virotherapy
Gene Transfer
Global Cancer Gene Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Diagnostics Centers
Research Institutes
Global Cancer Gene Therapy Market: Manufacturers Segment Analysis (Company and Product introduction, Cancer Gene Therapy Sales Volume, Revenue, Price and Gross Margin):
Adaptimmune
GlaxoSmithKline
Bluebird bio
Merck
Celgene
Shanghai Sunway Biotech
BioCancell
Shenzhen SiBiono GeneTech
SynerGene Therapeutics
OncoGenex Pharmaceuticals
Genelux Corporation
Cell Genesys
Advantagene
GenVec
BioCancell
Celgene
Epeius Biotechnologies
Introgen Therapeutics
Ziopharm Oncology
Shenzhen SiBiono GeneTech
Altor Bioscience
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF CANCER GENE THERAPY
1.1 Definition of Cancer Gene Therapy in This Report
1.2 Commercial Types of Cancer Gene Therapy
1.2.1 Gene Induced Immunotherapy
1.2.2 Oncolytic Virotherapy
1.2.3 Gene Transfer
1.3 Downstream Application of Cancer Gene Therapy
1.3.1 Hospitals
1.3.2 Diagnostics Centers
1.3.3 Research Institutes
1.4 Development History of Cancer Gene Therapy
1.5 Market Status and Trend of Cancer Gene Therapy 2013-2023
1.5.1 Global Cancer Gene Therapy Market Status and Trend 2013-2023
1.5.2 Regional Cancer Gene Therapy Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Cancer Gene Therapy 2013-2017
2.2 Sales Market of Cancer Gene Therapy by Regions
2.2.1 Sales Volume of Cancer Gene Therapy by Regions
2.2.2 Sales Value of Cancer Gene Therapy by Regions
2.3 Production Market of Cancer Gene Therapy by Regions
2.4 Global Market Forecast of Cancer Gene Therapy 2018-2023
2.4.1 Global Market Forecast of Cancer Gene Therapy 2018-2023
2.4.2 Market Forecast of Cancer Gene Therapy by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Cancer Gene Therapy by Types
3.2 Sales Value of Cancer Gene Therapy by Types
3.3 Market Forecast of Cancer Gene Therapy by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Cancer Gene Therapy by Downstream Industry
4.2 Global Market Forecast of Cancer Gene Therapy by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Cancer Gene Therapy Market Status by Countries
5.1.1 North America Cancer Gene Therapy Sales by Countries (2013-2017)
5.1.2 North America Cancer Gene Therapy Revenue by Countries (2013-2017)
5.1.3 United States Cancer Gene Therapy Market Status (2013-2017)
5.1.4 Canada Cancer Gene Therapy Market Status (2013-2017)
5.1.5 Mexico Cancer Gene Therapy Market Status (2013-2017)
5.2 North America Cancer Gene Therapy Market Status by Manufacturers
5.3 North America Cancer Gene Therapy Market Status by Type (2013-2017)
5.3.1 North America Cancer Gene Therapy Sales by Type (2013-2017)
5.3.2 North America Cancer Gene Therapy Revenue by Type (2013-2017)
5.4 North America Cancer Gene Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Cancer Gene Therapy Market Status by Countries
6.1.1 Europe Cancer Gene Therapy Sales by Countries (2013-2017)
6.1.2 Europe Cancer Gene Therapy Revenue by Countries (2013-2017)
6.1.3 Germany Cancer Gene Therapy Market Status (2013-2017)
6.1.4 UK Cancer Gene Therapy Market Status (2013-2017)
6.1.5 France Cancer Gene Therapy Market Status (2013-2017)
6.1.6 Italy Cancer Gene Therapy Market Status (2013-2017)
6.1.7 Russia Cancer Gene Therapy Market Status (2013-2017)
6.1.8 Spain Cancer Gene Therapy Market Status (2013-2017)
6.1.9 Benelux Cancer Gene Therapy Market Status (2013-2017)
6.2 Europe Cancer Gene Therapy Market Status by Manufacturers
6.3 Europe Cancer Gene Therapy Market Status by Type (2013-2017)
6.3.1 Europe Cancer Gene Therapy Sales by Type (2013-2017)
6.3.2 Europe Cancer Gene Therapy Revenue by Type (2013-2017)
6.4 Europe Cancer Gene Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Cancer Gene Therapy Market Status by Countries
7.1.1 Asia Pacific Cancer Gene Therapy Sales by Countries (2013-2017)
7.1.2 Asia Pacific Cancer Gene Therapy Revenue by Countries (2013-2017)
7.1.3 China Cancer Gene Therapy Market Status (2013-2017)
7.1.4 Japan Cancer Gene Therapy Market Status (2013-2017)
7.1.5 India Cancer Gene Therapy Market Status (2013-2017)
7.1.6 Southeast Asia Cancer Gene Therapy Market Status (2013-2017)
7.1.7 Australia Cancer Gene Therapy Market Status (2013-2017)
7.2 Asia Pacific Cancer Gene Therapy Market Status by Manufacturers
7.3 Asia Pacific Cancer Gene Therapy Market Status by Type (2013-2017)
7.3.1 Asia Pacific Cancer Gene Therapy Sales by Type (2013-2017)
7.3.2 Asia Pacific Cancer Gene Therapy Revenue by Type (2013-2017)
7.4 Asia Pacific Cancer Gene Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Cancer Gene Therapy Market Status by Countries
8.1.1 Latin America Cancer Gene Therapy Sales by Countries (2013-2017)
8.1.2 Latin America Cancer Gene Therapy Revenue by Countries (2013-2017)
8.1.3 Brazil Cancer Gene Therapy Market Status (2013-2017)
8.1.4 Argentina Cancer Gene Therapy Market Status (2013-2017)
8.1.5 Colombia Cancer Gene Therapy Market Status (2013-2017)
8.2 Latin America Cancer Gene Therapy Market Status by Manufacturers
8.3 Latin America Cancer Gene Therapy Market Status by Type (2013-2017)
8.3.1 Latin America Cancer Gene Therapy Sales by Type (2013-2017)
8.3.2 Latin America Cancer Gene Therapy Revenue by Type (2013-2017)
8.4 Latin America Cancer Gene Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Cancer Gene Therapy Market Status by Countries
9.1.1 Middle East and Africa Cancer Gene Therapy Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Cancer Gene Therapy Revenue by Countries (2013-2017)
9.1.3 Middle East Cancer Gene Therapy Market Status (2013-2017)
9.1.4 Africa Cancer Gene Therapy Market Status (2013-2017)
9.2 Middle East and Africa Cancer Gene Therapy Market Status by Manufacturers
9.3 Middle East and Africa Cancer Gene Therapy Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Cancer Gene Therapy Sales by Type (2013-2017)
9.3.2 Middle East and Africa Cancer Gene Therapy Revenue by Type (2013-2017)
9.4 Middle East and Africa Cancer Gene Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF CANCER GENE THERAPY
10.1 Global Economy Situation and Trend Overview
10.2 Cancer Gene Therapy Downstream Industry Situation and Trend Overview
CHAPTER 11 CANCER GENE THERAPY MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Cancer Gene Therapy by Major Manufacturers
11.2 Production Value of Cancer Gene Therapy by Major Manufacturers
11.3 Basic Information of Cancer Gene Therapy by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Cancer Gene Therapy Major Manufacturer
11.3.2 Employees and Revenue Level of Cancer Gene Therapy Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 CANCER GENE THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Adaptimmune
12.1.1 Company profile
12.1.2 Representative Cancer Gene Therapy Product
12.1.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Adaptimmune
12.2 GlaxoSmithKline
12.2.1 Company profile
12.2.2 Representative Cancer Gene Therapy Product
12.2.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.3 Bluebird bio
12.3.1 Company profile
12.3.2 Representative Cancer Gene Therapy Product
12.3.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Bluebird bio
12.4 Merck
12.4.1 Company profile
12.4.2 Representative Cancer Gene Therapy Product
12.4.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Merck
12.5 Celgene
12.5.1 Company profile
12.5.2 Representative Cancer Gene Therapy Product
12.5.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Celgene
12.6 Shanghai Sunway Biotech
12.6.1 Company profile
12.6.2 Representative Cancer Gene Therapy Product
12.6.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Shanghai Sunway Biotech
12.7 BioCancell
12.7.1 Company profile
12.7.2 Representative Cancer Gene Therapy Product
12.7.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of BioCancell
12.8 Shenzhen SiBiono GeneTech
12.8.1 Company profile
12.8.2 Representative Cancer Gene Therapy Product
12.8.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Shenzhen SiBiono GeneTech
12.9 SynerGene Therapeutics
12.9.1 Company profile
12.9.2 Representative Cancer Gene Therapy Product
12.9.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of SynerGene Therapeutics
12.10 OncoGenex Pharmaceuticals
12.10.1 Company profile
12.10.2 Representative Cancer Gene Therapy Product
12.10.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of OncoGenex Pharmaceuticals
12.11 Genelux Corporation
12.11.1 Company profile
12.11.2 Representative Cancer Gene Therapy Product
12.11.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Genelux Corporation
12.12 Cell Genesys
12.12.1 Company profile
12.12.2 Representative Cancer Gene Therapy Product
12.12.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Cell Genesys
12.13 Advantagene
12.13.1 Company profile
12.13.2 Representative Cancer Gene Therapy Product
12.13.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Advantagene
12.14 GenVec
12.14.1 Company profile
12.14.2 Representative Cancer Gene Therapy Product
12.14.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of GenVec
12.15 BioCancell
12.15.1 Company profile
12.15.2 Representative Cancer Gene Therapy Product
12.15.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of BioCancell
12.16 Celgene
12.17 Epeius Biotechnologies
12.18 Introgen Therapeutics
12.19 Ziopharm Oncology
12.20 Shenzhen SiBiono GeneTech
12.21 Altor Bioscience
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER GENE THERAPY
13.1 Industry Chain of Cancer Gene Therapy
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF CANCER GENE THERAPY
14.1 Cost Structure Analysis of Cancer Gene Therapy
14.2 Raw Materials Cost Analysis of Cancer Gene Therapy
14.3 Labor Cost Analysis of Cancer Gene Therapy
14.4 Manufacturing Expenses Analysis of Cancer Gene Therapy
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Cancer Gene Therapy in This Report
1.2 Commercial Types of Cancer Gene Therapy
1.2.1 Gene Induced Immunotherapy
1.2.2 Oncolytic Virotherapy
1.2.3 Gene Transfer
1.3 Downstream Application of Cancer Gene Therapy
1.3.1 Hospitals
1.3.2 Diagnostics Centers
1.3.3 Research Institutes
1.4 Development History of Cancer Gene Therapy
1.5 Market Status and Trend of Cancer Gene Therapy 2013-2023
1.5.1 Global Cancer Gene Therapy Market Status and Trend 2013-2023
1.5.2 Regional Cancer Gene Therapy Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Cancer Gene Therapy 2013-2017
2.2 Sales Market of Cancer Gene Therapy by Regions
2.2.1 Sales Volume of Cancer Gene Therapy by Regions
2.2.2 Sales Value of Cancer Gene Therapy by Regions
2.3 Production Market of Cancer Gene Therapy by Regions
2.4 Global Market Forecast of Cancer Gene Therapy 2018-2023
2.4.1 Global Market Forecast of Cancer Gene Therapy 2018-2023
2.4.2 Market Forecast of Cancer Gene Therapy by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Cancer Gene Therapy by Types
3.2 Sales Value of Cancer Gene Therapy by Types
3.3 Market Forecast of Cancer Gene Therapy by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Cancer Gene Therapy by Downstream Industry
4.2 Global Market Forecast of Cancer Gene Therapy by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Cancer Gene Therapy Market Status by Countries
5.1.1 North America Cancer Gene Therapy Sales by Countries (2013-2017)
5.1.2 North America Cancer Gene Therapy Revenue by Countries (2013-2017)
5.1.3 United States Cancer Gene Therapy Market Status (2013-2017)
5.1.4 Canada Cancer Gene Therapy Market Status (2013-2017)
5.1.5 Mexico Cancer Gene Therapy Market Status (2013-2017)
5.2 North America Cancer Gene Therapy Market Status by Manufacturers
5.3 North America Cancer Gene Therapy Market Status by Type (2013-2017)
5.3.1 North America Cancer Gene Therapy Sales by Type (2013-2017)
5.3.2 North America Cancer Gene Therapy Revenue by Type (2013-2017)
5.4 North America Cancer Gene Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Cancer Gene Therapy Market Status by Countries
6.1.1 Europe Cancer Gene Therapy Sales by Countries (2013-2017)
6.1.2 Europe Cancer Gene Therapy Revenue by Countries (2013-2017)
6.1.3 Germany Cancer Gene Therapy Market Status (2013-2017)
6.1.4 UK Cancer Gene Therapy Market Status (2013-2017)
6.1.5 France Cancer Gene Therapy Market Status (2013-2017)
6.1.6 Italy Cancer Gene Therapy Market Status (2013-2017)
6.1.7 Russia Cancer Gene Therapy Market Status (2013-2017)
6.1.8 Spain Cancer Gene Therapy Market Status (2013-2017)
6.1.9 Benelux Cancer Gene Therapy Market Status (2013-2017)
6.2 Europe Cancer Gene Therapy Market Status by Manufacturers
6.3 Europe Cancer Gene Therapy Market Status by Type (2013-2017)
6.3.1 Europe Cancer Gene Therapy Sales by Type (2013-2017)
6.3.2 Europe Cancer Gene Therapy Revenue by Type (2013-2017)
6.4 Europe Cancer Gene Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Cancer Gene Therapy Market Status by Countries
7.1.1 Asia Pacific Cancer Gene Therapy Sales by Countries (2013-2017)
7.1.2 Asia Pacific Cancer Gene Therapy Revenue by Countries (2013-2017)
7.1.3 China Cancer Gene Therapy Market Status (2013-2017)
7.1.4 Japan Cancer Gene Therapy Market Status (2013-2017)
7.1.5 India Cancer Gene Therapy Market Status (2013-2017)
7.1.6 Southeast Asia Cancer Gene Therapy Market Status (2013-2017)
7.1.7 Australia Cancer Gene Therapy Market Status (2013-2017)
7.2 Asia Pacific Cancer Gene Therapy Market Status by Manufacturers
7.3 Asia Pacific Cancer Gene Therapy Market Status by Type (2013-2017)
7.3.1 Asia Pacific Cancer Gene Therapy Sales by Type (2013-2017)
7.3.2 Asia Pacific Cancer Gene Therapy Revenue by Type (2013-2017)
7.4 Asia Pacific Cancer Gene Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Cancer Gene Therapy Market Status by Countries
8.1.1 Latin America Cancer Gene Therapy Sales by Countries (2013-2017)
8.1.2 Latin America Cancer Gene Therapy Revenue by Countries (2013-2017)
8.1.3 Brazil Cancer Gene Therapy Market Status (2013-2017)
8.1.4 Argentina Cancer Gene Therapy Market Status (2013-2017)
8.1.5 Colombia Cancer Gene Therapy Market Status (2013-2017)
8.2 Latin America Cancer Gene Therapy Market Status by Manufacturers
8.3 Latin America Cancer Gene Therapy Market Status by Type (2013-2017)
8.3.1 Latin America Cancer Gene Therapy Sales by Type (2013-2017)
8.3.2 Latin America Cancer Gene Therapy Revenue by Type (2013-2017)
8.4 Latin America Cancer Gene Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Cancer Gene Therapy Market Status by Countries
9.1.1 Middle East and Africa Cancer Gene Therapy Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Cancer Gene Therapy Revenue by Countries (2013-2017)
9.1.3 Middle East Cancer Gene Therapy Market Status (2013-2017)
9.1.4 Africa Cancer Gene Therapy Market Status (2013-2017)
9.2 Middle East and Africa Cancer Gene Therapy Market Status by Manufacturers
9.3 Middle East and Africa Cancer Gene Therapy Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Cancer Gene Therapy Sales by Type (2013-2017)
9.3.2 Middle East and Africa Cancer Gene Therapy Revenue by Type (2013-2017)
9.4 Middle East and Africa Cancer Gene Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF CANCER GENE THERAPY
10.1 Global Economy Situation and Trend Overview
10.2 Cancer Gene Therapy Downstream Industry Situation and Trend Overview
CHAPTER 11 CANCER GENE THERAPY MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Cancer Gene Therapy by Major Manufacturers
11.2 Production Value of Cancer Gene Therapy by Major Manufacturers
11.3 Basic Information of Cancer Gene Therapy by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Cancer Gene Therapy Major Manufacturer
11.3.2 Employees and Revenue Level of Cancer Gene Therapy Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 CANCER GENE THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Adaptimmune
12.1.1 Company profile
12.1.2 Representative Cancer Gene Therapy Product
12.1.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Adaptimmune
12.2 GlaxoSmithKline
12.2.1 Company profile
12.2.2 Representative Cancer Gene Therapy Product
12.2.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.3 Bluebird bio
12.3.1 Company profile
12.3.2 Representative Cancer Gene Therapy Product
12.3.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Bluebird bio
12.4 Merck
12.4.1 Company profile
12.4.2 Representative Cancer Gene Therapy Product
12.4.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Merck
12.5 Celgene
12.5.1 Company profile
12.5.2 Representative Cancer Gene Therapy Product
12.5.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Celgene
12.6 Shanghai Sunway Biotech
12.6.1 Company profile
12.6.2 Representative Cancer Gene Therapy Product
12.6.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Shanghai Sunway Biotech
12.7 BioCancell
12.7.1 Company profile
12.7.2 Representative Cancer Gene Therapy Product
12.7.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of BioCancell
12.8 Shenzhen SiBiono GeneTech
12.8.1 Company profile
12.8.2 Representative Cancer Gene Therapy Product
12.8.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Shenzhen SiBiono GeneTech
12.9 SynerGene Therapeutics
12.9.1 Company profile
12.9.2 Representative Cancer Gene Therapy Product
12.9.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of SynerGene Therapeutics
12.10 OncoGenex Pharmaceuticals
12.10.1 Company profile
12.10.2 Representative Cancer Gene Therapy Product
12.10.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of OncoGenex Pharmaceuticals
12.11 Genelux Corporation
12.11.1 Company profile
12.11.2 Representative Cancer Gene Therapy Product
12.11.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Genelux Corporation
12.12 Cell Genesys
12.12.1 Company profile
12.12.2 Representative Cancer Gene Therapy Product
12.12.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Cell Genesys
12.13 Advantagene
12.13.1 Company profile
12.13.2 Representative Cancer Gene Therapy Product
12.13.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Advantagene
12.14 GenVec
12.14.1 Company profile
12.14.2 Representative Cancer Gene Therapy Product
12.14.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of GenVec
12.15 BioCancell
12.15.1 Company profile
12.15.2 Representative Cancer Gene Therapy Product
12.15.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of BioCancell
12.16 Celgene
12.17 Epeius Biotechnologies
12.18 Introgen Therapeutics
12.19 Ziopharm Oncology
12.20 Shenzhen SiBiono GeneTech
12.21 Altor Bioscience
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER GENE THERAPY
13.1 Industry Chain of Cancer Gene Therapy
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF CANCER GENE THERAPY
14.1 Cost Structure Analysis of Cancer Gene Therapy
14.2 Raw Materials Cost Analysis of Cancer Gene Therapy
14.3 Labor Cost Analysis of Cancer Gene Therapy
14.4 Manufacturing Expenses Analysis of Cancer Gene Therapy
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
